uniQureQURE
QURE
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
292% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $13.2M
281% more capital invested
Capital invested by funds: $193M [Q3] → $734M (+$541M) [Q4]
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
5.53% more ownership
Funds ownership: 79.83% [Q3] → 85.36% (+5.53%) [Q4]
5% more funds holding
Funds holding: 130 [Q3] → 137 (+7) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 47
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
108%
upside
Avg. target
$46
220%
upside
High target
$70
386%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 187 met price target | 386%upside $70 | Buy Reiterated | 21 Apr 2025 |
Chardan Capital Daniil Gataulin 14% 1-year accuracy 7 / 49 met price target | 164%upside $38 | Buy Maintained | 1 Apr 2025 |
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target | 108%upside $30 | Equal-Weight Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 5 articles about QURE published over the past 30 days
Positive
Zacks Investment Research
2 days ago
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Seeking Alpha
2 days ago
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Neutral
Seeking Alpha
4 days ago
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact.
Positive
Benzinga
6 days ago
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday
Neutral
GlobeNewsWire
6 days ago
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
Negative
Zacks Investment Research
1 month ago
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~
Positive
Seeking Alpha
1 month ago
uniQure N.V.: A Potential Huntington's Play
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Positive
Seeking Alpha
2 months ago
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.
Positive
Benzinga
2 months ago
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.
Charts implemented using Lightweight Charts™